Table 1.
Baseline characteristics of patients (n = 100).
| Characteristics | Number of Patients (%) |
|---|---|
| Age (≥70 years) | 59 (59.0) |
| Sex (Male) | 84 (84.0) |
| HBs antigen (Positive) | 20 (20.0) |
| HCV antibody (Positive) | 30 (30.0) |
| Alcoholic liver disease (Present) | 35 (35.0) |
| Esophageal varix (Present) | 39 (39.0) |
| Gastric varix (Present) | 7 (7.0) |
| Autoimmune diseases (Present) | 0 (0.0) |
| History of previous curative therapy (Present) | 54 (54.0) |
| History of previous TACE (Present) | 65 (65.0) |
| Child–Pugh class (A/B) | 84 (84.0)/16 (16.0) |
| Modified ALBI grade (1/2a/2b/3) | 29 (29.0)/27 (27.0)/43 (43.0)/1 (1.0) |
| ECOG-PS (0/1) | 86 (86.0)/14 (14.0) |
| BCLC stage (A/B/C) | 3 (3.0)/44 (44.0)/53 (53.0) |
| Maximum tumor size (>6 cm) | 74 (74.0) |
| Tumor number (>6) | 47 (47.0) |
| Intrahepatic tumor volume (≥50%) | 3 (3.0) |
| Macrovascular invasion (Present) | 15 (15.0) |
| Extrahepatic spread (Present) | 41 (41.0) |
| AFP concentration (≥400 ng/mL) | 28 (28.0) |
| Initial dose of atezolizumab (Standard dose) | 100 (100.0) |
| Initial dose of bevacizumab (Reduced dose) | 5 (5.0) |
| Number of chemotherapy lines | |
| First-line | 58 (58.0) |
| Second- or later-line | 42 (42.0) |
| History of sorafenib therapy (Present) | 14 (14.0) |
| History of regorafenib therapy (Present) | 4 (4.0) |
| History of lenvatinib therapy (Present) | 36 (36.0) |
| History of ramucirumab therapy (Present) | 2 (2.0) |
Variables are expressed as number (%). Abbreviations: AFP, alpha-fetoprotein; ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Cancer; ECOG-PS, Eastern Cooperative Oncology Group performance status; HCV, hepatitis C virus; HBs, hepatitis B surface; TACE, transarterial chemoembolization.